Cinclus Pharma Holding AB is hosting a virtual event featuring Professor Prateek Sharma to discuss the treatment landscape and unmet medical needs for erosive GERD patients, highlighting their drug ...

"Cinclus Pharma has now entered late-stage clinical development following the initiation of its first Phase III study, and patient recruitment has so far progressed well. Topline results are expected ...

Cinclus Pharma Holding AB ( ($SE:CINPHA) ) has provided an announcement. Cinclus Pharma Holding AB has announced the appointment of its Nomination ...

"Gastroesophageal Reflux Disease (GERD) Market"The market for Gastroesophageal Reflux Disease (GERD) is poised for growth during the forecast period (2024-2034), due to escalating prevalence, aging ...

Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing the next-generation treatments for acid-related diseases, today announced that the first patient has been ...

Cinclus Pharma Holding AB has chosen Zentiva k.s. to handle manufacturing and commercialization duties in Europe for linaprazan glurate, which is being developed to treat severe erosive ...

Former Sanofi subsidiary Zentiva has signed off on up to 220 million euros for the rights to commercialize and manufacture an ex-AstraZeneca asset for gastric-acid-related diseases in Europe. Under ...

The chart above depicts the distribution of Revenue for companies operating in the Healthcare Sector in the Developed economic region. Over 2,040 companies were considered in this analysis, and 1,975 ...

Ownership Discover who owns Cinclus Pharma Holding AB. Access the ownership overview, view the top Cinclus Pharma Holding AB shareholders, institutional holders, and leading mutual fund investors.

Mercer UCITS CCF - Mercer Passive Global Small Cap Equity UCITS CCF 0.00% NaN Jun 30, 2024 28.00 ...